We serve Chemical Name:3-Methoxy-4-methyl-1,5-naphthyridine CAS:893566-31-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Methoxy-4-methyl-1,5-naphthyridine
CAS.NO:893566-31-9
Synonyms:3-Methoxy-4-methyl-1,5-naphthyridine
Molecular Formula:C10H10N2O
Molecular Weight:174.19900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:35.01000
Exact Mass:174.07900
LogP:1.94680
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Methoxy-4-methyl-1,5-naphthyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Methoxy-4-methyl-1,5-naphthyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Methoxy-4-methyl-1,5-naphthyridine Use and application,3-Methoxy-4-methyl-1,5-naphthyridine technical grade,usp/ep/jp grade.
Related News: The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 3-Methoxy-4-methyl-1,5-naphthyridine manufacturer Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance. 3-Methoxy-4-methyl-1,5-naphthyridine supplier Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 3-Methoxy-4-methyl-1,5-naphthyridine vendor The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 3-Methoxy-4-methyl-1,5-naphthyridine factory Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 3-Methoxy-4-methyl-1,5-naphthyridine manufacturer Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance. 3-Methoxy-4-methyl-1,5-naphthyridine supplier Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 3-Methoxy-4-methyl-1,5-naphthyridine vendor The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. 3-Methoxy-4-methyl-1,5-naphthyridine factory Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.
